In addition, simultaneous boosting of the CD8+ T cell response, using a TRP-peptide vaccination strategy, along with anti-PD-1 and ACF in hypoxic B16-F10 tumors, promoted tumor regression in vivo. This evidence concerns the gene CD8A and neoplasm.